GlassScriptPhysician profile
Stanley B Allen
NPI 1326034505
$4,241.19
in general payments reported to CMS, 2019-2025
32 companies · $969 in 2025
The $969 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $751 · 2022: $698 · 2023: $897 · 2024: $925 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,680 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,680.32 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $672.28 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.26 | 2021-2025 | Jardiance |
| Pfizer INC. | $454.86 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $409.73 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Glaxosmithkline, LLC. | $408.03 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $284.59 | 2022-2025 | |
| Lilly USA, LLC | $259.23 | 2021-2025 | Jardiance, Mounjaro, Trulicity |
| Novartis Pharmaceuticals Corporation | $241.58 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $144.34 | 2021-2024 | Capvaxive, Gardasil 9, Gardasil |
| Amgen INC. | $130.53 | 2021-2024 | Otezla, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $116.37 | 2021-2022 | |
| Exact Sciences Corporation | $106.73 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $57.39 | 2023-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $46.27 | 2021 | |
| Insulet Corporation | $43.65 | 2021-2025 | Omnipod |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $43.08 | 2021-2023 | Rexulti |
| Ironwood Pharmaceuticals, INC | $42.50 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $37.47 | 2025 | Airsupra |
| Corcept Therapeutics | $36.55 | 2025 | Korlym |
| Dexcom, INC. | $35.85 | 2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $20.46 | 2021 | |
| Cgg Medical INC | $18.39 | 2022 | |
| Almatica Pharma LLC | $17.85 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.32 | 2025 | |
| Phathom Pharmaceuticals, INC. | $16.24 | 2025 | Voquezna |
| Coloplast Corp | $15.81 | 2023 | Interdry |
| Shield Therapeutics INC | $15.37 | 2023 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $14.33 | 2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.31 | 2025 | Xifaxan |
| Sanofi Pasteur INC. | $13.62 | 2023 | |
| Eisai INC. | $12.67 | 2021 | |
| Baxter Healthcare | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.